













## 4<sup>th</sup> International Conference

# **HUS-MPGN-TTP**

# & related disorders

Current diagnosis and therapy of hemolytic uremic syndrome (HUS), membranoproliferative glomerulonephritis (MPGN), thrombotic thrombocytopenic purpura (TTP), and related disorders



## **Programme:**

Sunday, June 9

13.00 - 18.00 Lectures and Free Communications

18.00 - 20.30 Welcome reception

Monday, June 10

08.30 - 16.30 Lectures and Free Communications

16.30 - 18.30 Postersession Wine & Cheese

18.45 Transfer to Gala Dinner/ Tyrolean Night

Tuesday, June 11

08.30 - 13.00 Lectures and Free Communications

Congress President: Reinhard.Wuerzner@i-med.ac.at, www.hus-online.at

### Registration open: April 1st - May 31th, 2013

Registration fee: EUR 250,00

Resident in training: EUR 150,00

Students: EUR 50,00

In the registration fee included are all meals, coffee breaks, welcome reception and Monday evening gala dinner.

#### Hotel accommodation (please mention "HUS-Meeting")

Hotel Grauer Bär, Universitätsstraße 5-7, 6020 Innsbruck

**\*** +43-512-5924-0

E-Mail: grauer-baer@innsbruck-hotels.at

www.innsbruck-hotels.at/hotel-grauer-baer/das-hotel/index.php?lang=de

#### Reduced rate for participants:

Single € 78 (including breakfast and all taxes)
Double € 120 (including breakfast and all taxes)

## Sunday, June 9

10:00 - 18:30		Registration open
13:00		Welcome from Innsbruck Medical University  Lochs/Würzner
ı.	Introducto	ory session - Basics
13:15	L1	Complement & Diagnostics Kirschfink
14:00	L2	Inherited complement-related renal diseases: genetics Rodriguez de Cordoba
14:30	L3	Acquired complement-related renal diseases: antibodies <u>Jozsi</u>
15:00	L4	Secondary causes of complement-related renal diseases Fremeaux-Bacchi
15:30	- 16:00	Coffee break
II.	Introductory	session - Clinics
16:00	L5	Classification & Pathology of complement-related renal diseases $\underline{\textit{Sethi}}$
16:30	L6	Animal studies in complement-related renal diseases <u>Pickering</u>
17:00	L7	Treatment of complement-related renal diseases <u>Licht</u>
17:30	FC1	Screening of genes encoding complement (regulatory) proteins in patients with C3 glomerulopathy Westra
17:45	FC2	Recessive mutations in DGKE cause aHUS <u>Lemaire</u>
18:00		Welcome reception

## Monday, June 10

III:	TTP	
08:30	L8	Inherited TTP (Upshaw Schulman Syndrome) in childhood <u>Schneppenheim</u>
09:00	L9	Clinical presentation and differential diagnostics in TTP <u>Coppo</u>
09:30	L10	Treatment of TTP <u>Knöbl</u>
10:00 - 10:30		Coffee break
IV:		ourses of complement-related renal diseases - cases irs: <u>Van de Kar</u> & N.N.
10:30	<b>C</b> 1	A 7 yr old boy with HUS and response to i.v. steroids <u>Safouh</u>
10:45	C2	An unusual case of thrombotic microangiopathy of unknown aetiology <u>Sørensen</u>
11:00	C3	Eculizumab and aHUS: a complicated case with frequent replapses <a href="Schalk">Schalk</a>
11:15	C4	A successful use of Eculizumab in a case of aHUS in pregnancy <u>Ardissino</u>
11:30	<b>C</b> 5	Successful treatment of MPGN type II associated with autoanti- bodies against complement factor C3b with immunoadsorption <u>Vinke</u>
11:45-13:00		Lunch break

## V. Typical HUS - Outbreak I

13:00	L11	Epidemiology of O104:H4 <u>Werber</u>	
13:30	L12	Molecular characteristics of O104:H4 <u>Karch</u>	
14:00	L13	Clinical data - adults <u>Stahl</u>	
14:30 - 15:00		Coffee break	
VI. Typical HUS - Outbreak II & Host responses			
15:00	L14	Clinical data - children <u>Kemper</u>	
15:30	FC3	Human serum amyloid protects human podocytes from shiga toxin 2 induced activation of mitogen-activated protein kinases and apoptosis <u>Dettmar</u>	
15:45	FC4	Shiga toxin 2 induces apoptosis and a proinflammatory phenotype in human glomerular endothelial cells <u>Betzen</u>	
16:00	L15	Innate & inflammatory immune responses <u>Palermo</u>	
16:30 - 18:30		Poster Session with wine and cheese	
18:30 - 18:45		Transfer: 5 min. walk to the funicular	
20:00		Tyrolean Night - Congress Dinner at the Seegrube, overlooking Innsbruck	

## Tuesday, June 11

108:30 L16 Downregulation of membrane inhibitor CD59 by shiga toxin 2 Orth-Höller and Würzner  108:55 L17 Endothelial injury & generation of complement-activating microparticles Thurman  109:20 L18 Blood cell derived microparticles in typical HUS Karpman  109:45 L19 Complement activation in STEC-HUS: from disease pathogenesis to therapy Noris  10:10 - 10:45 Coffee break  VIII. Treatment with Eculizumab  10:45 L20 Eculizumab in PNH Röth  11:15 L21 Eculizumab in DDD & MPGN Wivarelli and Emma  11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	VII.	Typical I	HUS & complement - updates
microparticles Thurman  09:20 L18 Blood cell derived microparticles in typical HUS Karpman  09:45 L19 Complement activation in STEC-HUS: from disease pathogenesis to therapy Noris  10:10 - 10:45 Coffee break  VIII. Treatment with Eculizumab  10:45 L20 Eculizumab in PNH Röth  11:15 L21 Eculizumab in DDD & MPGN Vivarelli and Emma  11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	08:30	L16	· · · · · · · · · · · · · · · · · · ·
Noris  L19 Complement activation in STEC-HUS: from disease pathogenesis to therapy Noris  10:10 - 10:45 Coffee break  VIII. Treatment with Eculizumab  10:45 L20 Eculizumab in PNH Röth  11:15 L21 Eculizumab in DDD & MPGN Vivarelli and Emma  11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	08:55	L17	microparticles
to therapy Noris  10:10 - 10:45 Coffee break  VIII. Treatment with Eculizumab  10:45 L20 Eculizumab in PNH Röth  11:15 L21 Eculizumab in DDD & MPGN Vivarelli and Emma  11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	09:20	L18	, , , , , , , , , , , , , , , , , , , ,
VIII. Treatment with Eculizumab  10:45 L20 Eculizumab in PNH Röth  11:15 L21 Eculizumab in DDD & MPGN Vivarelli and Emma  11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	09:45	L19	to therapy
10:45 L20 Eculizumab in PNH Röth  11:15 L21 Eculizumab in DDD & MPGN Vivarelli and Emma  11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	10:10 - 10:45		Coffee break
11:15 L21 Eculizumab in DDD & MPGN  Vivarelli and Emma  11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab  Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety  Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long- term improvements with Eculizumab  Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS  Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies  Wehling and Kirschfink	VIII.	Treatme	nt with Eculizumab
11:45 FC5 Frontline treatment for aHUS: plasma exchange or Eculizumab Paglialonga  12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	10:45	L20	
12:00 FC6 Long-term Eculizumab treatment of patients with aHUS with a long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	11:15	L21	
long disease duration & chronic kidney disease: efficacy &safety Licht  12:15 FC7 aHUS and progressing thrombotic microangiopathy (TMA): long-term improvements with Eculizumab Loirat  12:30 FC8 Discontinuation of Eculizumab maintenance treatment in patients with aHUS Testa  12:45 FC9 Eculizumab drug monitoring in complement-mediated nephropathies Wehling and Kirschfink	11:45	FC5	•
term improvements with Eculizumab  Loirat  12:30  FC8  Discontinuation of Eculizumab maintenance treatment in patients with aHUS  Testa  12:45  FC9  Eculizumab drug monitoring in complement-mediated nephropathies  Wehling and Kirschfink	12:00	FC6	long disease duration & chronic kidney disease: efficacy &safety
patients with aHUS <u>Testa</u> 12:45  FC9  Eculizumab drug monitoring in complement-mediated nephropathies  Wehling and <u>Kirschfink</u>	12:15	FC7	term improvements with Eculizumab
nephropathies Wehling and <u>Kirschfink</u>	12:30	FC8	patients with aHUS
12:00 14:00 Earowell and lunch	12:45	FC9	nephropathies
13.00 - 14.00 Farewell and lunch	13:00 - 14:00		Farewell and lunch